Evidence map›Paper›PMID 39039672›Full record

ReviewCurrent pharmaceutical design2024

Maximizing Treatment Options for IBD through Drug Repurposing.

Amir Hossein Barjasteh, Abdulridha Mohammed Al-Asady, Hanieh Latifi, Souad Al Okla, Nasser Al-Nazwani, Amir Avan, Majid Khazaei, Mikhail Ryzhikov, Hanieh Nadi-Yazdi, Seyed Mahdi Hassanian

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Anti-inflammatory effects of oridonin on anExperimental and therapeutic medicine · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Amir Hossein BarjastehFaculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Abdulridha Mohammed Al-AsadyDepartment of Medical Sciences, Faculty of Nursing, Warith Al-Anbiyaa University, Karbala, Iraq.
Hanieh LatifiFaculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Souad Al OklaCollege of Medicine and Health Sciences, National University of Science and Technology, Muscat, Oman.
Nasser Al-NazwaniDepartment of Biochemistry, College of Medicine and Health Sciences, National University of Science and Technology, Sohar, Oman.
Amir AvanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Majid KhazaeiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mikhail RyzhikovSchool of Medicine, Saint Louis University, St. Louis, MO 63103, USA.
Hanieh Nadi-YazdiDepartment of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyed Mahdi HassanianMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic inflammation characterizes Inflammatory Bowel Disease (IBD), encompassing Crohn's Disease (CD) and Ulcerative Colitis (UC). Despite modest activity of disease in most UC patients, exacerbations occur, especially in those with severe symptoms, necessitating interventions, like colectomy. Current treatments for IBD, predominantly small molecule therapies, impose significant economic burdens. Drug repurposing offers a cost-effective alternative, leveraging existing drugs for novel therapeutic applications. This approach capitalizes on shared molecular pathways across diseases, accelerating therapeutic discovery while minimizing costs and risks. This article provides an overview of IBD and explores drug repurposing as a promising avenue for more effective and affordable treatments. Through computational and animal studies, potential drug candidates are categorized, offering insights into IBD pathogenesis and treatment strategies.

Indexed as

Drug RepositioningInflammatory Bowel DiseasesAnimalsHumansCrohn's diseasedrug repurposinginflammationInflammatory bowel diseasesmall molecule therapies.ulcerative colitis

Identifiers

PMID39039672

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.